Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:ANIK
- CUSIP: 03525510
- Web: www.anikatherapeutics.com
Capitalization:- Market Cap: $676.87 million
- Outstanding Shares: 14,654,000
Average Prices:- 50 Day Moving Avg: $45.44
- 200 Day Moving Avg: $46.88
- 52 Week Range: $41.38 - $54.96
P/E:- Trailing P/E Ratio: 22.29
- Foreward P/E Ratio: 22.98
- P/E Growth: 2.33
Sales & Book Value:- Annual Revenue: $104.48 million
- Price / Sales: 6.48
- Book Value: $15.70 per share
- Price / Book: 2.94
Profitability:- EBIDTA: $51.71 million
- Net Margins: 33.64%
- Return on Equity: 17.21%
- Return on Assets: 15.71%
Debt:- Current Ratio: 21.25%
- Quick Ratio: 18.87%
Misc:- Average Volume: 116,611 shs.
- Beta: 1.85
- Short Ratio: 8.83
Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) issued its earnings results on Wednesday, May, 3rd. The company reported $0.37 EPS for the quarter, missing the Zacks' consensus estimate of $0.38 by $0.01. The firm earned $23.39 million during the quarter, compared to analysts' expectations of $23.89 million. Anika Therapeutics had a net margin of 33.64% and a return on equity of 17.21%. Anika Therapeutics's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 EPS. View Anika Therapeutics' Earnings History.
When will Anika Therapeutics make its next earnings announcement?
Are investors shorting Anika Therapeutics?
Anika Therapeutics saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 1,418,573 shares, an increase of 0.1% from the March 31st total of 1,416,891 shares. Based on an average daily trading volume, of 108,020 shares, the short-interest ratio is currently 13.1 days.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Repligen (RGEN), Innoviva (INVA), Emergent Biosolutions (EBS), Loxo Oncology (LOXO), Blueprint Medicines Corp (BPMC), Dermira (DERM), Amicus Therapeutics (FOLD), Coherus Biosciences (CHRS), Insys Therapeutics (INSY), Insmed Incorporated (INSM), Xencor (XNCR), Acceleron Pharma (XLRN), Forward Pharma A/S (FWP), Epizyme (EPZM), Aimmune Therapeutics (AIMT), Cellectis SA (CLLS), Immunomedics (IMMU) and ZIOPHARM Oncology (ZIOP).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Charles H. Sherwood Jr, President, Chief Executive Officer, Director
- Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
- Dana M. Alexander, Chief Operating Officer
- Edward Ahn Ph.D., Chief Technology and Strategy Officer
- Richard Hague, Chief Commercial Officer
- Joseph Lyon Bower Ph.D., Lead Independent Director
- Raymond J. Land, Independent Director
- Glenn R Larsen Ph.D., Independent Director
- Jeffrey Scott Thompson, Independent Director
- Steven E. Wheeler, Independent Director
Who owns Anika Therapeutics stock?
Anika Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (0.00%), Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), Dimensional Fund Advisors LP (0.00%), State Street Corp (2.38%) and BTIM Corp. (2.33%). Company insiders that own Anika Therapeutics stock include Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.
Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?
Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Vanguard Group Inc., AQR Capital Management LLC, Russell Investments Group Ltd., BTIM Corp., JPMorgan Chase & Co., Gotham Asset Management LLC and Citadel Advisors LLC. Company insiders that have sold Anika Therapeutics stock in the last year include Jeffery S Thompson and Joseph I Bower. View Insider Buying and Selling for Anika Therapeutics.
Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?
Anika Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Columbia Wanger Asset Management LLC, Wells Fargo & Company MN, Stifel Financial Corp, Ngam Advisors L.P., Renaissance Technologies LLC, Dimensional Fund Advisors LP and Spark Investment Management LLC. View Insider Buying and Selling for Anika Therapeutics.
How do I buy Anika Therapeutics stock?
Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of Anika Therapeutics stock can currently be purchased for approximately $46.19.
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Anika Therapeutics (NASDAQ:ANIK)Earnings History by Quarter for Anika Therapeutics (NASDAQ:ANIK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/25/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | $0.38 | $0.37 | $23.89 million | $23.39 million | View | Listen |  |
| 2/15/2017 | Q416 | $0.53 | $0.54 | $27.84 million | $28.70 million | View | N/A | |
| 10/26/2016 | Q316 | $0.47 | $0.59 | $26.60 million | $25.79 million | View | Listen | |
| 7/27/2016 | Q216 | $0.44 | $0.57 | $24.75 million | $26.60 million | View | Listen | |
| 4/27/2016 | Q116 | $0.28 | $0.45 | $19.26 million | $22.30 million | View | Listen | |
| 2/24/2016 | Q415 | $0.60 | $0.72 | $28.19 million | $25.60 million | View | Listen | |
| 10/28/2015 | Q315 | $0.34 | $0.55 | $22.36 million | $23.70 million | View | Listen | |
| 7/29/2015 | Q215 | $0.34 | $0.51 | $21.65 million | $22.90 million | View | Listen | |
| 4/28/2015 | Q115 | $0.21 | $0.23 | $16.20 million | $15.50 million | View | Listen | |
| 2/25/2015 | Q414 | $0.48 | $0.51 | $24.60 million | $23.30 million | View | Listen | |
| 10/29/2014 | Q314 | $0.33 | $0.40 | $20.33 million | $22.10 million | View | Listen | |
| 7/30/2014 | Q214 | $0.57 | $0.60 | $28.20 million | $26.27 million | View | Listen | |
| 4/29/2014 | Q114 | $0.25 | $0.97 | $16.03 million | $34.00 million | View | N/A | |
| 2/26/2014 | Q413 | $0.42 | $0.44 | $21.91 million | $21.30 million | View | Listen | |
| 10/31/2013 | Q313 | $0.14 | $0.33 | $16.96 million | $17.80 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.25 | $0.40 | $17.09 million | $20.80 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)2017 EPS Consensus Estimate: $1.98
2018 EPS Consensus Estimate: $1.73
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.34 | $0.42 | $0.38 |
| Q2 2017 | 2 | $0.47 | $0.50 | $0.49 |
| Q3 2017 | 2 | $0.42 | $0.50 | $0.46 |
| Q4 2017 | 2 | $0.62 | $0.68 | $0.65 |
| Q1 2018 | 1 | $0.32 | $0.32 | $0.32 |
| Q2 2018 | 1 | $0.47 | $0.47 | $0.47 |
| Q3 2018 | 1 | $0.44 | $0.44 | $0.44 |
| Q4 2018 | 1 | $0.50 | $0.50 | $0.50 |
(Data provided by Zacks Investment Research)
Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 76.53%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Jeffery S Thompson | Director | Sell | 10,725 | $47.39 | $508,257.75 | |
| 11/9/2016 | Joseph I Bower | Director | Sell | 540 | $43.39 | $23,430.60 | |
| 2/25/2016 | Raymond J Land | Director | Sell | 2,695 | $43.62 | $117,555.90 | |
| 2/27/2015 | Raymond J Land | Director | Sell | 4,621 | $39.49 | $182,483.29 | |
| 5/1/2014 | Charles H Sherwood | CEO | Sell | 83,780 | $44.32 | $3,713,129.60 | |
| 2/28/2014 | Charles H Sherwood | CEO | Sell | 200,000 | $41.70 | $8,340,000.00 | |
| 8/22/2013 | John C Moran | Director | Sell | 5,000 | $24.35 | $121,750.00 | |
| 8/8/2013 | Steve E Wheeler | Director | Sell | 26,984 | $23.61 | $637,092.24 | |
| 8/7/2013 | Steve E Wheeler | Director | Sell | 11,016 | $27.01 | $297,542.16 | |
| 8/6/2013 | Farmaceutici S.P.A. Fidia | Major Shareholder | Sell | 1,270,000 | $24.52 | $31,140,400.00 | |
| 7/15/2013 | Charles H Sherwood | CEO | Sell | 75,000 | $20.11 | $1,508,250.00 | |
| 7/9/2013 | Charles H Sherwood | CEO | Sell | 49,185 | $18.06 | $888,281.10 | |
| 7/5/2013 | Charles H Sherwood | CEO | Sell | 34,662 | $18.01 | $624,262.62 | |
| 6/19/2013 | Charles H Sherwood | CEO | Sell | 1,847 | $18.00 | $33,246.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
| Source: |
|
| Date | Headline |
|---|
 | Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
finance.yahoo.com - May 25 at 4:05 PM |
 | Anika Therapeutics Inc (ANIK) Director Sells $508,257.75 in Stock
www.americanbankingnews.com - May 23 at 7:47 PM |
| Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts
finance.yahoo.com - May 23 at 3:40 PM |
| Anika Announces Publication of Phase III Data Demonstrating the Efficacy and Safety of CINGAL® for the Treatment of Knee Pain Associated with Osteoarthritis
finance.yahoo.com - May 22 at 3:34 PM |
| Zacks: Anika Therapeutics Inc (ANIK) Given $52.00 Average Target Price by Brokerages
www.americanbankingnews.com - May 16 at 8:34 PM |
| Biotech Movers: Anika Up on Strong Analyst Ratings
finance.yahoo.com - May 12 at 4:08 PM |
| Zacks Investment Research Lowers Anika Therapeutics Inc (ANIK) to Sell
www.americanbankingnews.com - May 8 at 5:28 PM |
| Short Interest in Anika Therapeutics Inc (ANIK) Increases By 0.1%
www.americanbankingnews.com - May 8 at 8:52 AM |
| Research Analysts Offer Predictions for Anika Therapeutics Inc's Q2 2017 Earnings (ANIK)
www.americanbankingnews.com - May 8 at 8:30 AM |
 | Anika Therapeutics Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 7 at 11:29 AM |
| Edited Transcript of ANIK earnings conference call or presentation 4-May-17 1:00pm GMT
finance.yahoo.com - May 6 at 1:40 AM |
| Anika Therapeutics Inc (ANIK) Issues Earnings Results
www.americanbankingnews.com - May 4 at 9:00 PM |
| Investor Network: Anika Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 3:37 PM |
| Anika Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:37 PM |
| Anika posts 1Q profit
finance.yahoo.com - May 3 at 8:37 PM |
 | Global Hyaluranoic Acid Raw Material Market expected to be worth 7.25 Billion USD by 2024
www.bizjournals.com - May 3 at 9:31 AM |
| Favorable News Coverage Very Likely to Affect Anika Therapeutics (ANIK) Share Price
www.americanbankingnews.com - May 2 at 2:20 PM |
| Anika Therapeutics Inc (ANIK) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 11:25 AM |
| Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : April 28, 2017
finance.yahoo.com - April 28 at 9:33 PM |
| Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : April 27, 2017
finance.yahoo.com - April 27 at 3:56 PM |
| Anika Therapeutics (ANIK) Earning Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 5:14 PM |
| Anika Therapeutics (ANIK) Given News Impact Rating of 0.24
www.americanbankingnews.com - April 21 at 10:17 AM |
| Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3 - Yahoo Finance
finance.yahoo.com - April 20 at 1:34 AM |
| Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3
finance.yahoo.com - April 19 at 8:32 PM |
| Anika Therapeutics (ANIK) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 18 at 11:08 AM |
| Zacks: Analysts Set $57.00 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - April 17 at 10:34 PM |
| Anika Therapeutics (ANIK) Receiving Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 14 at 4:36 PM |
 | 6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 - Nasdaq
www.nasdaq.com - March 31 at 8:45 PM |
| Implied Volatility Surging for Anika Therapeutics (ANIK) Stock ... - Nasdaq
www.nasdaq.com - March 15 at 3:43 PM |
| Implied Volatility Surging for Anika Therapeutics (ANIK) Stock Options
finance.yahoo.com - March 14 at 3:28 PM |
| ANIKA THERAPEUTICS, INC. Financials
finance.yahoo.com - March 3 at 3:45 PM |
| Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017
finance.yahoo.com - February 28 at 8:38 PM |
| Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock ... - Yahoo Finance
finance.yahoo.com - February 27 at 3:39 PM |
 | Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market Opening Bell
feeds.benzinga.com - February 27 at 10:55 AM |
| ANIKA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 24 at 8:44 PM |
| Edited Transcript of ANIK earnings conference call or presentation 16-Feb-17 2:00pm GMT
finance.yahoo.com - February 17 at 10:06 AM |
| Anika Therapeutics Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 16 at 3:36 PM |
| Q4 2016 Anika Therapeutics Inc Earnings Release - After Market Close
us.rd.yahoo.com - February 16 at 8:26 AM |
 | Anika Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - February 16 at 8:26 AM |
| 4:09 pm Anika Therapeutics beats by $0.01, beats on revs; provides FY17 outlook
us.rd.yahoo.com - February 16 at 8:26 AM |
| ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - February 16 at 8:26 AM |
| ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - February 8 at 8:47 PM |
 | Form SC 13G/A Anika Therapeutics, Inc. Filed by: THOMPSON SIEGEL & WALMSLEY LLC - StreetInsider.com
www.streetinsider.com - February 7 at 3:42 PM |
| Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y
finance.yahoo.com - February 3 at 3:42 PM |
Anika Therapeutics (ANIK) Chart for Monday, May, 29, 2017
